These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
169 related articles for article (PubMed ID: 6301931)
1. Neurobehavioral actions of cannabichromene and interactions with delta 9-tetrahydrocannabinol. Davis WM; Hatoum NS Gen Pharmacol; 1983; 14(2):247-52. PubMed ID: 6301931 [TBL] [Abstract][Full Text] [Related]
2. Pharmacological evaluation of the natural constituent of Cannabis sativa, cannabichromene and its modulation by Δ(9)-tetrahydrocannabinol. DeLong GT; Wolf CE; Poklis A; Lichtman AH Drug Alcohol Depend; 2010 Nov; 112(1-2):126-33. PubMed ID: 20619971 [TBL] [Abstract][Full Text] [Related]
3. Reversal of SR 141716A-induced head-twitch and ear-scratch responses in mice by delta 9-THC and other cannabinoids. Janoyan JJ; Crim JL; Darmani NA Pharmacol Biochem Behav; 2002; 71(1-2):155-62. PubMed ID: 11812518 [TBL] [Abstract][Full Text] [Related]
4. Subacute cannabinoid treatment: anticonvulsant activity and withdrawal excitability in mice. Karler R; Turkanis SA Br J Pharmacol; 1980 Mar; 68(3):479-84. PubMed ID: 6301593 [TBL] [Abstract][Full Text] [Related]
5. Cannabinoids of diverse structure inhibit two DOI-induced 5-HT(2A) receptor-mediated behaviors in mice. Darmani NA Pharmacol Biochem Behav; 2001 Feb; 68(2):311-7. PubMed ID: 11267636 [TBL] [Abstract][Full Text] [Related]
6. Antidepressant-like effect of delta9-tetrahydrocannabinol and other cannabinoids isolated from Cannabis sativa L. El-Alfy AT; Ivey K; Robinson K; Ahmed S; Radwan M; Slade D; Khan I; ElSohly M; Ross S Pharmacol Biochem Behav; 2010 Jun; 95(4):434-42. PubMed ID: 20332000 [TBL] [Abstract][Full Text] [Related]
7. Behavioral, biochemical, and molecular modeling evaluations of cannabinoid analogs. Martin BR; Compton DR; Thomas BF; Prescott WR; Little PJ; Razdan RK; Johnson MR; Melvin LS; Mechoulam R; Ward SJ Pharmacol Biochem Behav; 1991 Nov; 40(3):471-8. PubMed ID: 1666911 [TBL] [Abstract][Full Text] [Related]
8. Perinatal exposure to cannabichromene and delta 9-tetrahydrocannabinol: separate and combined effects on viability of pups and on male reproductive system at maturity. Hatoum NS; Davis WM; Elsohly MA; Turner CE Toxicol Lett; 1981 May; 8(3):141-6. PubMed ID: 6264652 [TBL] [Abstract][Full Text] [Related]
9. Anticonvulsant properties of delta 9-tetrahydrocannabinol and other cannabinoids. Karler R; Cely W; Turkanis SA Life Sci; 1974 Sep; 15(5):931-47. PubMed ID: 4549949 [No Abstract] [Full Text] [Related]
10. Cerebellar CB(1) receptor mediation of Delta(9)-THC-induced motor incoordination and its potentiation by ethanol and modulation by the cerebellar adenosinergic A(1) receptor in the mouse. Dar MS Brain Res; 2000 May; 864(2):186-94. PubMed ID: 10802025 [TBL] [Abstract][Full Text] [Related]
11. Effects of delta9-tetrahydrocannabinol (THC) on several rodent learning paradigms. Robichaud RC; Hefner MA; Anderson JE; Goldberg ME Pharmacology; 1973; 10(1):1-11. PubMed ID: 4751537 [No Abstract] [Full Text] [Related]
12. AB-CHMINACA, AB-PINACA, and FUBIMINA: Affinity and Potency of Novel Synthetic Cannabinoids in Producing Δ9-Tetrahydrocannabinol-Like Effects in Mice. Wiley JL; Marusich JA; Lefever TW; Antonazzo KR; Wallgren MT; Cortes RA; Patel PR; Grabenauer M; Moore KN; Thomas BF J Pharmacol Exp Ther; 2015 Sep; 354(3):328-39. PubMed ID: 26105953 [TBL] [Abstract][Full Text] [Related]
13. Discriminative stimulus- and open-field effects of the enantiomers of 11-hydroxy-delta-8-tetrahydrocannabinol in pigeons and gerbils. Järbe TU; Mechoulam R; Zahalka J Pharmacol Biochem Behav; 1994 Jan; 47(1):113-9. PubMed ID: 8115412 [TBL] [Abstract][Full Text] [Related]
14. Evaluation of agonist-antagonist properties of nitrogen mustard and cyano derivatives of delta 8-tetrahydrocannabinol. Wiley JL; Compton DR; Gordon PM; Siegel C; Singer M; Dutta A; Lichtman AH; Balster RL; Razdan RK; Martin BR Neuropharmacology; 1996; 35(12):1793-804. PubMed ID: 9076759 [TBL] [Abstract][Full Text] [Related]
15. Absence of delta -9-tetrahydrocannabinol dysphoric effects in dynorphin-deficient mice. Zimmer A; Valjent E; Konig M; Zimmer AM; Robledo P; Hahn H; Valverde O; Maldonado R J Neurosci; 2001 Dec; 21(23):9499-505. PubMed ID: 11717384 [TBL] [Abstract][Full Text] [Related]
16. Effects of cannabinoids on lithium-induced conditioned rejection reactions in a rat model of nausea. Parker LA; Mechoulam R; Schlievert C; Abbott L; Fudge ML; Burton P Psychopharmacology (Berl); 2003 Mar; 166(2):156-62. PubMed ID: 12528012 [TBL] [Abstract][Full Text] [Related]
17. Pharmacological potency of R- and S-3'-hydroxy-delta 9-tetrahydrocannabinol: additional structural requirement for cannabinoid activity. Martin BR; Kallman MJ; Kaempf GF; Harris LS; Dewey WL; Razdan RK Pharmacol Biochem Behav; 1984 Jul; 21(1):61-5. PubMed ID: 6087379 [TBL] [Abstract][Full Text] [Related]
18. Neurobehavioral effects of delta 9-THC and cannabinoid (CB1) receptor gene expression in mice. Onaivi ES; Chakrabarti A; Gwebu ET; Chaudhuri G Behav Brain Res; 1995 Dec; 72(1-2):115-25. PubMed ID: 8788864 [TBL] [Abstract][Full Text] [Related]
19. Functional effects of synthetic cannabinoids versus Δ Schreiber S; Bader M; Lenchinski T; Meningher I; Rubovitch V; Katz Y; Cohen E; Gabet Y; Rotenberg M; Wolf EU; Pick CG Addict Biol; 2019 May; 24(3):414-425. PubMed ID: 29423994 [TBL] [Abstract][Full Text] [Related]
20. Individual differences in the effects of cannabinoids on motor activity, dopaminergic activity and DARPP-32 phosphorylation in distinct regions of the brain. Polissidis A; Chouliara O; Galanopoulos A; Rentesi G; Dosi M; Hyphantis T; Marselos M; Papadopoulou-Daifoti Z; Nomikos GG; Spyraki C; Tzavara ET; Antoniou K Int J Neuropsychopharmacol; 2010 Oct; 13(9):1175-91. PubMed ID: 19941698 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]